New Generation Cell Therapy:
Bioartificial Pancreas to Cure Type 1 Diabetes

Why needed?

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.

There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.

Our solution​

The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.

This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.

Project overview

  • Consortium

    9 partners from 5 countries

  • Budget

    € 6.8 million

  • Duration

    01.01.2020 – 31.12.2024

News

VANGUARD partners meet for the first time

Representatives from the eight VANGUARD partners travelled from across Europe to Igls in Austria to officially kick-off the project. The meeting took place on the